Blood Cancer: Long-term Study of Zanubrutinib

We are evaluating the long-term safety and effectiveness of Zanubrutinib in patients with B-cell malignancies. This study is for those who have previously participated in a related trial.

>2 years6-10 visitsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboCost ReimbursementPartially RemoteStandard MedicinesOralHematologyOncology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Zanubrutinib
Zanubrutinib is a substance that treats certain B‑cell blood cancers by blocking a protein that helps cancerous B cells grow.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Fakultni Nemocnice Brno
Interni hematologicka a onkologicka klinika
Brno, Czechia
Fakultni Nemocnice Ostrava
Klinika hematoonkologie FNO a LF OU
Hlučín, Czechia
Fakultni Nemocnice Hradec Kralove
IV. interni hematologicka klinika
Hradec Králové, Czechia
Sponsor: BeOne Medicines AG
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.